Trial Summary
What is the purpose of this trial?
This is a research study, is testing a program to improve lung health through smoking cessation and providing education around lung screening. In this research study involves Studying the Enhanced Smoking Cessation Approaches to Promote Empowerment (ESCAPE) program compared to usual care. The ESCAPE program was developed help women with HIV quit smoking. Women in the ESCAPE program quit smoking and stayed quit for longer (up to 3 months). For this study, investigators have added a lung screening to the ESCAPE program and want to test if this will improve lung health through increasing quit rates and lung screening. .
Research Team
Mary E Cooley, PhD
Principal Investigator
Dana-Farber Cancer Institute
Eligibility Criteria
This trial is for high-risk smokers aged 55-77 who smoke at least 5 cigarettes a day and have a history of heavy smoking (≥30 pack years). Participants must be English-speaking, own a mobile phone with video call capability, have active health insurance, and can complete an interview. They should not have had lung cancer or low-dose CT screening before.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- ESCAPE (Behavioural Intervention)
- Standard Care (Behavioural Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Dana-Farber Cancer Institute
Lead Sponsor
Dr. Benjamin L. Ebert
Dana-Farber Cancer Institute
Chief Executive Officer
MD from Harvard Medical School, PhD from Oxford University
Dr. Craig A. Bunnell
Dana-Farber Cancer Institute
Chief Medical Officer since 2012
MD from Harvard Medical School, MPH from Harvard School of Public Health, MBA from MIT Sloan School of Management
American Association for Cancer Research
Collaborator